Related Experiment Video

Updated: Feb 27, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.4K

Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes

Rachel H Tan1,2,3, Jillian J Kril4, Yue Yang1,3

  • 1Brain and Mind Centre, Sydney Medical School, The University of Sydney, Sydney, Australia.

Alzheimer'S & Dementia (Amsterdam, Netherlands)
|June 28, 2017
PubMed
Abstract

Insights

Amyloid beta (Aβ) is common in frontotemporal dementia (FTD) and increases with age, similar to controls. This study provides a pathological reference for interpreting in vivo imaging in FTD.

Area of Science:

  • Neuropathology
  • Neuroimaging
  • Dementia Research

Background:

  • Distinguishing frontotemporal dementia (FTD) from Alzheimer's disease (AD) using in vivo amyloid beta (Aβ) imaging is challenging.
  • Data on Aβ prevalence and severity in pathologically confirmed FTD is lacking.

Purpose of the Study:

  • To determine the prevalence and severity of Aβ pathology in FTD.
  • To assess the pathological accuracy of 11C-Pittsburgh compound B (PiB)-PET imaging in FTD.

Main Methods:

  • Aβ was assessed in 98 autopsy-confirmed FTD cases and 36 controls.
  • 11C-Pittsburgh compound B (PiB)-PET imaging was evaluated in 15 FTD cases.

Main Results:

  • Aβ was found in similar proportions of FTD cases and controls, increasing with age.
  • High PiB retention correlated with Alzheimer's disease pathology.
  • Histological Aβ correlated strongly with PiB retention.

Conclusions:

  • This study establishes a pathological reference for interpreting in vivo Aβ imaging in FTD.
  • Aβ imaging findings in FTD can be better understood with this pathological correlation.
Keywords:
11C-Pittsburgh compound BAlzheimer's diseaseAmyloid βDiagnosticFrontotemporal dementia syndromes

More Related Videos

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease08:25

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

4.1K
Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

4.8K

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.2K
Amyloid Fibrils03:03

Amyloid Fibrils

6.8K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
609
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K